Outlook Therapeutics, Inc.(OTLK)Earnings, Financials & Key RatiosOutlook Therapeutics, Inc. (OTLK) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q2
the company's precarious liquidity position, evidenced by a cash balance of only $8.7 million against a $36.9 million debt load, suggests imminent dilution risk for shareholders.
Outlook Therapeutics, Inc. (OTLK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Outlook Therapeutics, Inc. (OTLK) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.16vs $0.12-33.3% | $128,000vs $4M-97.1% |
| Q1 2026 | Feb 17, 2026 | $0.22vs $0.17-29.4% | $1Mvs $3M-138.4% |
| Q4 2025 | Dec 19, 2025 | $0.22vs $0.26+15.4% | $91,787vs $6M-101.6% |
| Q3 2025 | Aug 14, 2025 | $0.44vs $0.42-4.8% | $2Mvs $6M-74.3% |
Recent stock market news and headlines for Outlook Therapeutics, Inc. (OTLK)
Outlook Therapeutics stock surges 35% after the FDA accepts the resubmitted Lytenava BLA for wet AMD for review, setting a July 29, 2026, decision date.
Outlook Therapeutics Inc. (NASDAQ:OTLK) shares are rising in Wednesday premarket trading after the company announced the FDA accepted its resubmitted Biologics License Application (BLA) for ONS-5010/LYTENAVA.
ISELIN, N. J. , June 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the U. S.
ISELIN, N.J., June 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ for the treatment of neovascular age-related macular degeneration (nAMD), or wet AMD.
Key metrics vs top competitors for Outlook Therapeutics, Inc. (OTLK)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.42 | $58.42M | -0.79 | — | -4416.22% | — | — | |
| $3.99 | $435.68M | -1.99 | — | — | -70.79% | — | |
| $4.36 | $96.26M | -0.66 | -72.22% | — | — | — | |
| $11.47 | $962.85M | -3.39 | — | — | -128.57% | — | |
| $123.72 | $9.1B | -21.15 | — | — | -42.78% | — | |
| $649.81 | $67.52B | 15.67 | 0.99% | 29.65% | 14.32% | — |
Outlook Therapeutics, Inc. (OTLK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Outlook Therapeutics, Inc. (OTLK) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 29, 2026·SEC
May 28, 2026·SEC
May 26, 2026·SEC
Get notified when OTLK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Outlook Therapeutics, Inc. (OTLK) stock FAQ — growth, dividends, profitability & financials explained
Outlook Therapeutics, Inc. (OTLK) reported $0.3M in revenue for fiscal year 2025. This represents a 96% decrease from $9.1M in 2014.
Outlook Therapeutics, Inc. (OTLK) reported a net loss of $61.0M for fiscal year 2025.
Outlook Therapeutics, Inc. (OTLK) had negative free cash flow of $22.77T in fiscal year 2025, likely due to heavy capital investments.
